Bayer beefs up Ob/Gyn sales calls

Share this article:
Bayer runs "corrective" Yaz ad, agrees to preclearance
Bayer runs "corrective" Yaz ad, agrees to preclearance
Pfizer has usurped Merck as the most admired drug company among obstetricians and gynecologists, according to SDI's Pharmaceutical Company Image 2011 study, while Bayer increased its sales presence in that specialty significantly.

Bayer came in second among Ob/Gyns asked to name three pharma firms they considered “top companies (it was fourth last year),” followed by Merck and Warner Chilcott, which called on Ob/Gyns more than any other corporation during the year to April 2011, accounting for 13% of all sales calls to those docs.

Warner Chilcott was followed in volume of calls by Bayer, which made 12% of all sales calls – up 19%, for that year-to-April period, over the previous 12 months.

“Bayer's improved standing is impressive, particularly over only one year's time,” said SDI's Jason Fox, associated director, Syndicated Analytics group. “The company's reps have increased their presence among Ob/Gyns and must be making a positive impression.”

Bayer reps were most likely to discuss two newer contraceptives, Beyaz or Natazia, or Yaz during those visits. Beyaz was discussed during 30% of the company's details to Ob/Gyns, Natazia in 24% and Yaz in 19%.

Teva and Pfizer each accounted for 7% of sales calls to Ob/Gyns and Merck 5%.

The survey of 9,800 physicians, including 385 Ob/Gyns, also found that perception of the pharma industry improved among physicians in general for the first time since 2004, however meagerly, as 58% of respondents reported a somewhat positive or extremely positive impression – up two points over 2010.
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?